Pulse.

a daily field guide to health research that matters

◆ Console

‹ Sun · 15 Nov 2026
Promising but preliminary

Efficacy of homoharringtonine (HHT)-based induction regimen in acute myeloid leukemia (AML) with double-mutated CCAAT/enhancer-binding protein alpha (CEBPA): A prospective multicenter, single-arm phase II trial.

A chemotherapy regimen achieves unusually high remission rates in a subset of acute leukemia with specific genetic mutations, offering hope for this favorable-risk group.

Prospective multicenter Phase II trial (n=61, NCT04415008, median follow-up 32 months) established that HAD induction in CEBPAdm AML achieves exceptional CR rates and durable survival, meeting prespecified endpoints. CEBPA double mutation represents ~6–10% of AML; prior HHT-based retrospective data are now prospectively confirmed at multiple Chinese haematology centres, supporting HAD as a preferred regimen in this favorable-risk subset.

What the study was

Study design
Prospective multicenter single-arm Phase II trial
Category
Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)
Maturity
Validated
Journal
Cancer Pathog Ther

Why it surfaced

First prospective multicenter Phase II trial confirming HHT-based induction in a specific AML molecular subtype (CEBPAdm); PMC full text available; enrolling from 9 Chinese tertiary centres; primary outcomes met. Novelty point: HHT mechanism specifically suppresses CEBPA expression, providing mechanistic rationale for the observed benefit.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.